Corrigendum to “Graphene oxide as a nanocarrier for controlled release and targeted delivery of an anticancer active agent, chlorogenic acid” [J. Mater. Sci. Eng. C 74(2017) 177–185]

2017 ◽  
Vol 75 ◽  
pp. 1525
Author(s):  
Farahnaz Barahuie ◽  
Bullo Saifullah ◽  
Dena Dorniani ◽  
Sharida Fakurazi ◽  
Govindarajan Karthivashan ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Controlled Release ◽  
Chlorogenic Acid ◽  
Targeted Delivery ◽  
Active Agent

scholarly journals Graphene oxide as a nanocarrier for controlled release and targeted delivery of an anticancer active agent, chlorogenic acid

2017 ◽  
Vol 74 ◽  
pp. 177-185 ◽  
Author(s):  
Farahnaz Barahuie ◽  
Bullo Saifullah ◽  
Dena Dorniani ◽  
Sharida Fakurazi ◽  
Govindarajan Karthivashan ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Controlled Release ◽  
Chlorogenic Acid ◽  
Targeted Delivery ◽  
Active Agent

Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide

2016 ◽  
Vol 59 ◽  
pp. 652-660 ◽  
Author(s):  
Yao Lv ◽  
Lei Tao ◽  
S.W. Annie Bligh ◽  
Huihui Yang ◽  
Qixia Pan ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Controlled Release ◽  
Cancer Cells ◽  
Targeted Delivery

Microsponges: An Overview

2017 ◽  
Vol 4 (4) ◽  
Author(s):  
Hamid Hussain ◽  
Divya Juyal ◽  
Archana Dhyani
Keyword(s):  
Controlled Release ◽  
Delivery System ◽  
Oral Delivery ◽  
Active Agent ◽  
Topical Delivery ◽  
Water Soluble ◽  
Wide Range ◽  
Porous Beads

Microsponge and Nanosponge delivery System was originally developed for topical delivery of drugs can also be used for controlled oral delivery of drugs using water soluble and bioerodible polymers. Microsponge delivery system (MDS) can entrap wide range of drugs and then release them onto the skin over a time by difussion mechanism to the skin. It is a unique technology for the controlled release of topical agents and consists of nano or micro porous beads loaded with active agent and also use for oral delivery of drugs using bioerodible polymers.

scholarly journals A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells

2020 ◽  
Vol 22 (1) ◽  
pp. 340
Author(s):  
Ilya Nifant’ev ◽  
Andrei Siniavin ◽  
Eduard Karamov ◽  
Maxim Kosarev ◽  
Sergey Kovalchuk ◽  
...  
Keyword(s):  
Controlled Release ◽  
Block Copolymers ◽  
Phosphoric Acid ◽  
Hiv Infection ◽  
Targeted Delivery ◽  
Release Formulation ◽  
Poly Ethylene ◽  
Long Acting ◽  
Hiv Drugs ◽  
Anti Hiv

Despite the world’s combined efforts, human immunodeficiency virus (HIV), the causative agent of AIDS, remains one of the world’s most serious public health challenges. High genetic variability of HIV complicates the development of anti-HIV vaccine, and there is an actual clinical need for increasing the efficiency of anti-HIV drugs in terms of targeted delivery and controlled release. Tenofovir (TFV), a nucleotide-analog reverse transcriptase inhibitor, has gained wide acceptance as a drug for pre-exposure prophylaxis or treatment of HIV infection. In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-b-PEPA) as candidates for developing a long-acting/controlled-release formulation of TFV. Two types of mPEG-b-PEPA with numbers of ethylene phosphoric acid (EPA) fragments of 13 and 49 were synthesized by catalytic ring-opening polymerization, and used for preparing four types of adducts with TFD. Antiviral activity of [mPEG-b-PEPA]TFD or tenofovir disoproxil fumarate (TDF) was evaluated using the model of experimental HIV infection in vitro (MT-4/HIV-1IIIB). Judging by the values of the selectivity index (SI), TFD exhibited an up to 14-fold higher anti-HIV activity in the form of mPEG-b-PEPA adducts, thus demonstrating significant promise for further development of long-acting/controlled-release injectable TFV formulations.

Preparation and the controlled release effect study of graphene oxide-modified poly(ε-caprolactone)

2017 ◽  
Vol 67 (5) ◽  
pp. 307-312 ◽  
Author(s):  
Fangqing Weng ◽  
Jing Yin ◽  
Feng Bao ◽  
Jie Gao ◽  
Rui Ma ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Controlled Release ◽  
Effect Study

scholarly journals Graphene Oxide as a Nanocarrier for Controlled Loading and Targeted Delivery of Typhonium giganteum Drugs

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Xiaohua Gu ◽  
Rui Cao ◽  
Fu Li ◽  
Yan Li ◽  
Hongge Jia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Graphene Oxide ◽  
Targeted Delivery ◽  
Drug Carrier ◽  
Dual Function ◽  
Natural Environments ◽  
Scanning Calorimetry ◽  
Environment Friendly ◽  
A549 Lung ◽  
Scanning Electron

In this study, Typhonium giganteum containing dual-function nanofibers composed of poly(butylene carbonate), polylactic acid, and graphene oxide (PBC/PLA/GO) were successfully fabricated by electrospinning. The results from thermogravimetric analysis (TG), differential scanning calorimetry (DSC), and Fourier-transform infrared spectroscopy (FTIR) indicate that no interactions occurred between PBC and PLA. The nanofiber microstructure upon which graphene oxide was evenly distributed was studied by scanning electron microscopy (SEM) and showed good silk properties. The nanofibers can be used as a drug carrier since loaded Typhonium giganteum fibers possess excellent biocompatibility. Such nanofibers are effective in inhibiting the proliferation of A549 lung cancer cells, and thus they have potential for replacing chemotherapy-based treatments of lung cancer. In addition, the PBC/PLA/GO nanofibers degrade in physiological and natural environments, which is an important feature when engineering tissues and environment-friendly materials.

Magnetically controlled release of recombinant tissue plasminogen activator from chitosan nanocomposites for targeted thrombolysis

2016 ◽  
Vol 4 (15) ◽  
pp. 2578-2590 ◽  
Author(s):  
Jyh-Ping Chen ◽  
Chih-Hsin Liu ◽  
Hao-Lung Hsu ◽  
Tony Wu ◽  
Yu-Jen Lu ◽  
...  
Keyword(s):  
Controlled Release ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Targeted Delivery ◽  
Chitosan Nanoparticles ◽  
Recombinant Tissue Plasminogen Activator ◽  
Triggered Release ◽  
Magnetic Chitosan ◽  
Tissue Plasminogen ◽  
Thrombolysis Therapy

Targeted delivery and triggered release of rtPA-encapsulated magnetic chitosan nanoparticles with the guidance of a magnet could be used for remote-controlled thrombolysis therapy.

Sign in / Sign up

Export Citation Format

Share Document